{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:30Z","timestamp":1791409890039,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014786","name":"Northern Border University","doi-asserted-by":"publisher","award":["NBU-CRP-2026-2043"],"award-info":[{"award-number":["NBU-CRP-2026-2043"]}],"id":[{"id":"10.13039\/501100014786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110255","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:59:40Z","timestamp":1784559580000},"page":"110255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigation of novel 4-substituted piperazine\u2013pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy"],"prefix":"10.1016","volume":"181","author":[{"given":"Shivangi","family":"Makwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruma","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrija","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirani","family":"Punniyamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premlata","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110255_bb0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jncc.2025.02.002","article-title":"Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN","volume":"5","author":"Zhang","year":"2025","journal-title":"Journal of the National Cancer Center"},{"key":"10.1016\/j.bioorg.2026.110255_bb0010","first-page":"31","article-title":"Breast cancer statistics, 2015: convergence of incidence rates between Black and White women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110255_bb0015","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2174\/0118715206389899250522091159","article-title":"Maternal embryonic leucine zipper kinase (MELK) as a promising therapeutic target in triple negative breast Cancer","volume":"25","author":"Das","year":"2025","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0020","doi-asserted-by":"crossref","first-page":"40003","DOI":"10.1074\/jbc.M507274200","article-title":"Substrate specificity and activity regulation of protein kinase MELK","volume":"280","author":"Beullens","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00109-012-0949-1","article-title":"The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer","volume":"91","author":"Kuner","year":"2013","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110255_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jnr.21471","article-title":"Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells","volume":"86","author":"Nakano","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0035","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/bcr2350","article-title":"Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer","volume":"11","author":"Pickard","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0040","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1158\/1078-0432.CCR-09-1107","article-title":"Identification of novel kinase targets for the treatment of estrogen receptor\u2013negative breast cancer","volume":"15","author":"Speers","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0045","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/jcmm.14878","article-title":"Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1\/S cell cycle arrest via the ATM\/CHK2\/p53 pathway","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110255_bb0050","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/bcr1650","article-title":"Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family","volume":"9","author":"Lin","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.200412115","article-title":"Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation","volume":"170","author":"Nakano","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110255_bb0060","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.18632\/oncotarget.790","article-title":"Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer","volume":"3","author":"Chung","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110255_bb0065","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24179","article-title":"CRISPR\/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials","volume":"6","author":"Lin","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2026.110255_bb0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s12094-024-03664-5","article-title":"Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application","volume":"27","author":"Su","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.110255_bb0075","first-page":"801","article-title":"Sustainable nanoparticle synthesis of palladium and platinum using mung bean (Vigna radiata L.) for circular metal recovery","volume":"9","author":"\u00c7ene","year":"2025","journal-title":"Int. J. Agric. Environ. Food Sci."},{"key":"10.1016\/j.bioorg.2026.110255_bb0080","unstructured":"\u0130. BALNAN, Banana peel\u2013assisted synthesis of ZnS and 5 mol% Mg-doped ZnS for photocatalytic degradation of Congo red, MAS Journal of Applied Sciences 11 (2026) 68\u201380. doi:https:\/\/doi.org\/10.5281\/zenodo.18920789."},{"key":"10.1016\/j.bioorg.2026.110255_bb0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejmech.2018.08.023","article-title":"Pyrrolopyrimidines: an update on recent advancements in their medicinal attributes","volume":"157","author":"Pathania","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107867","article-title":"Pyrrolo[2,3-d]pyrimidines as potential kinase inhibitors in cancer drug discovery: a critical review","volume":"153","author":"Sai Madhurya","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0095","doi-asserted-by":"crossref","DOI":"10.2174\/0929867324666170303162100","article-title":"Pyrrolo[2,3-d]pyrimidines as kinase inhibitors","volume":"24","author":"Musumeci","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0100","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.bmcl.2012.11.032","article-title":"Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity","volume":"23","author":"Tari","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110255_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-022-06543-1","article-title":"Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial","volume":"193","author":"Campone","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.110255_bb0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast Cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110255_bb0115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110255_bb0120","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cncr.35238","article-title":"FDA approves capivasertib with fulvestrant for breast cancer","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110255_bb0125","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-19-3953","article-title":"Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with Fulvestrant in patients with AKT1 E17K-mutant, ER-positive metastatic breast Cancer","volume":"26","author":"Smyth","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.bioorg.2026.110255_bb0135","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1021\/acs.jmedchem.4c00075","article-title":"Akt inhibitor advancements: from Capivasertib approval to covalent-allosteric promises","volume":"67","author":"Pervanidis","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0140","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110255_bb0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta\u00ae)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110255_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2015.07.026","article-title":"Piperazine scaffold: a remarkable tool in generation of diverse pharmacological agents","volume":"102","author":"Shaquiquzzaman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11094-022-02597-z","article-title":"Piperazine heterocycles as potential anticancer agents: a review","volume":"56","author":"Al-Ghorbani","year":"2022","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.bioorg.2026.110255_bb0160","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.drudis.2020.09.029","article-title":"MELK\/MPK38 in cancer: from mechanistic aspects to therapeutic strategies","volume":"25","author":"Thangaraj","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110255_bb0165","first-page":"1","article-title":"Molecular modelling and structure-activity relationship of pyrrolo[2,3- d ]pyrimidine derivatives as potent DNA gyrase B inhibitors","author":"Makwana","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110255_bb0170","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10593-018-2320-0","article-title":"An improved synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine","volume":"54","author":"Zhang","year":"2018","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.bioorg.2026.110255_bb0175","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0960-9822(95)00252-1","article-title":"S-phase-promoting cyclin-dependent kinases prevent re-replication by inhibiting the transition of replication origins to a pre-replicative state","volume":"5","author":"Dahmann","year":"1995","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bioorg.2026.110255_bb0180","article-title":"MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2026.110255_bb0185","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.bmc.2017.03.018","article-title":"Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth","volume":"25","author":"Edupuganti","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1142\/S2737416524500807","article-title":"Synthesis, characterization, molecular modeling studies and bioactivity of a novel bicyclic compound of \u03b4-lactam with oxazepine ring containing sulphur substitute using an economic method","volume":"24","author":"Muslim","year":"2025","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142453","article-title":"Comprehensive exploration of thiophene-tagged 2-(2-hydrazinyl)thiazole derivatives: synthesis, structural characterization, antimicrobial potential, and computational insights","volume":"1341","author":"Shinde","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110255_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202403150","article-title":"Integrated computational approach for designing potent EGFR-TK inhibitors: QSAR, docking, ADMET, and molecular dynamics studies","volume":"22","author":"Patil","year":"2025","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110255_bb0205","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11696-024-03754-2","article-title":"Antidiabetic activity of the extracted oil from an Indian indigenous plant, Amberboa ramosa: evidences from in silico, in vitro and enzyme inhibition kinetic studies","volume":"79","author":"Paul","year":"2025","journal-title":"Chem. Pap."},{"key":"10.1016\/j.bioorg.2026.110255_bb0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/acsmedchemlett.4c00354","article-title":"Optimizing linezolid: transforming it into a selective MAO-B inhibitor via a toxicity-to-activity optimization approach","volume":"16","author":"Dhangar","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110255_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140083","article-title":"Synthesis, antimicrobial activity, molecular docking and MD simulation studies, in silico ADME investigations and thermo-acoustic studies of heterocyclic dihydropyrimidine substituted 1,3,4-thiadiazole scaffolds","volume":"1321","author":"Saiyad","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110255_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140295","article-title":"One-pot multicomponent synthesis of novel pyrazole-linked thiazolyl-pyrazolines: molecular docking and cytotoxicity assessment on breast and lung cancer cell-lines","volume":"1322","author":"Kamani","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110255_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202501510","article-title":"Molecular docking, dynamics, and cytotoxicity assessment of pyrazolo[1,5- a ]pyrimidine derivatives against breast Cancer","author":"Patel","year":"2025","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110255_bb0230","doi-asserted-by":"crossref","first-page":"31412","DOI":"10.1038\/s41598-024-83046-7","article-title":"Integrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics","volume":"15","author":"Shah","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110255_bb0235","doi-asserted-by":"crossref","first-page":"2300423","DOI":"10.1002\/ardp.202300423","article-title":"Novel quinazoline\u2013chromene hybrids as anticancer agents: synthesis, biological activity, molecular docking, dynamics and ADME studies","volume":"356","author":"Tokal\u0131","year":"2023","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2026.110255_bb0240","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2026.110255_bb0245","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/0118715206304193240715043704","article-title":"Anti-inflammatory and anti-proliferative role of essential oil of leaves of Cleistocalyx operculatus (Roxb.) Merr. & Perry","volume":"25","author":"Pandey","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143779","article-title":"Anticancer potential of 1,2,3-triazole-tethered isonicotinate hybrids: synthesis, in-silico studies, in-vitro studies and MD simulation","volume":"1349","author":"Hadavani","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110255_bb0255","doi-asserted-by":"crossref","unstructured":"A. Newbold, B.P. Martin, C. Cullinane, M. Bots, Detection of apoptotic cells using propidium iodide staining, Cold Spring Harb. Protoc. 2014 (2014) pdb.prot082545. doi:https:\/\/doi.org\/10.1101\/pdb.prot082545.","DOI":"10.1101\/pdb.prot082545"},{"key":"10.1016\/j.bioorg.2026.110255_bb0260","doi-asserted-by":"crossref","unstructured":"P. Pozarowski, Z. Darzynkiewicz, Analysis of Cell Cycle by Flow Cytometry, in: Checkpoint Controls and Cancer, Humana Press, New Jersey, n.d.: pp. 301\u2013312. doi:https:\/\/doi.org\/10.1385\/1-59259-811-0:301.","DOI":"10.1385\/1-59259-811-0:301"},{"key":"10.1016\/j.bioorg.2026.110255_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105358","article-title":"Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents","volume":"116","author":"Pathak","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110255_bb0270","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western blot: technique, theory, and trouble shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1016\/j.bioorg.2026.110255_bb0275","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1080\/07391102.2023.2224899","article-title":"New tetrahydroisoquinoline-4-carbonitrile derivatives as potent agents against cyclin-dependent kinases, crystal structures, and computational studies","volume":"42","author":"El Bakri","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110255_bb0280","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1080\/07391102.2023.2229437","article-title":"Dalbergia sissoo phytochemicals as EGFR inhibitors: an in vitro and in silico approach","volume":"42","author":"Naik","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110255_bb0285","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1080\/07391102.2023.2231542","article-title":"A review on computational studies and bioinformatics analysis of potential drugs against monkeypox virus","volume":"42","author":"Hossain","year":"2024","journal-title":"J. Biomol. Struct. Dyn."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:10:43Z","timestamp":1791407443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"alternative-id":["S0045206826007911"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110255","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of novel 4-substituted piperazine\u2013pyrrolo[2,3-d]pyrimidine N-phenylacetamides as MELK-targeted anticancer agents for breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110255"}}